{"id":"NCT02809053","sponsor":"Archigen Biotech Limited","briefTitle":"A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma","officialTitle":"A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-01-18","primaryCompletion":"2019-07-17","completion":"2020-01-10","firstPosted":"2016-06-22","resultsPosted":"2020-10-08","lastUpdate":"2020-10-08"},"enrollment":315,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Lymphoma, Follicular"],"interventions":[{"type":"BIOLOGICAL","name":"SAIT101","otherNames":[]},{"type":"BIOLOGICAL","name":"MabThera®","otherNames":["Rituximab"]}],"arms":[{"label":"SAIT101","type":"EXPERIMENTAL"},{"label":"MabThera®","type":"ACTIVE_COMPARATOR"}],"summary":"This is a Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the statistical equivalence of efficacy, safety and immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in asymptomatic patients with Low Tumor Burden Follicular Lymphoma.","primaryOutcome":{"measure":"Overall Response Rate (ORR) at Week 28","timeFrame":"Baseline (Day 0) to Week 28.","effectByArm":[{"arm":"SAIT101","deltaMin":66.3,"sd":null},{"arm":"MabThera","deltaMin":70.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":25,"countries":["United States","Australia","Chile","Czechia","France","Germany","Hungary","Italy","Mexico","South Africa","South Korea","Spain","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":157},"commonTop":["Infusion related reaction","Fatigue","Pruritus","Headache","Diarrhoea"]}}